# Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease

> **NCT06499233** · PHASE4 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 800 (estimated)

## Conditions studied

- Pneumonia, Pneumocystis
- Autoimmune Inflammatory Rheumatic Disease
- Autoimmune Diseases
- Connective Tissue Disease
- Prevention

## Interventions

- **DRUG:** Trimethoprim/Sulfamethoxazole

## Key facts

- **NCT ID:** NCT06499233
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-20
- **Primary completion:** 2026-07-20
- **Final completion:** 2026-12-31
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06499233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06499233, "Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06499233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*